O	0	8	Reducing
B-condition	9	18	Radiation
I-condition	19	29	Dermatitis
O	30	35	Using
O	36	37	a
B-intervention	38	42	Film
I-intervention	42	43	-
I-intervention	43	50	forming
I-intervention	51	59	Silicone
I-intervention	60	63	Gel
O	64	70	During
O	71	77	Breast
O	78	90	Radiotherapy
O	90	91	:
O	92	93	A
O	94	99	Pilot
O	100	110	Randomized
O	110	111	-
O	111	121	controlled
O	122	127	Trial
O	127	128	.

O	129	131	To
O	132	140	evaluate
O	141	148	whether
O	149	156	topical
O	157	160	use
O	161	163	of
O	164	165	a
O	166	170	film
O	170	171	-
O	171	178	forming
O	179	187	silicone
O	188	191	gel
O	192	193	(
O	193	202	StrataXRT
O	202	203	®
O	203	204	)
O	205	210	could
O	211	217	reduce
O	218	227	radiation
O	228	238	dermatitis
O	239	247	compared
O	248	250	to
O	251	252	a
B-control	253	265	moisturizing
I-control	266	271	cream
O	272	273	(
O	273	274	X
O	274	275	-
O	275	279	derm
O	279	280	®
O	280	281	)
O	282	284	in
B-eligibility	285	293	patients
I-eligibility	294	303	receiving
I-eligibility	304	309	whole
I-eligibility	310	316	breast
I-eligibility	317	329	radiotherapy
O	329	330	.

O	331	332	A
O	333	338	total
O	339	341	of
B-total-participants	342	344	56
O	345	353	patients
O	354	358	with
O	359	365	breast
O	366	372	cancer
O	373	377	were
O	378	388	randomized
O	389	391	to
O	392	395	use
O	396	405	StrataXRT
O	406	408	or
O	409	410	X
O	410	411	-
O	411	415	derm
O	415	416	.

O	417	420	The
O	421	429	severity
O	430	432	of
O	433	442	radiation
O	443	453	dermatitis
O	454	457	was
O	458	464	graded
O	465	470	using
O	471	484	physiological
O	485	489	skin
O	490	500	parameters
O	500	501	,
O	502	511	clinician
O	511	512	-
O	512	520	assessed
O	521	527	visual
O	528	534	rating
O	535	541	scales
O	542	545	and
O	546	553	patient
O	553	554	-
O	554	562	reported
O	563	571	symptoms
O	571	572	.

O	573	580	Changes
O	581	583	in
O	584	589	these
O	590	600	parameters
O	601	605	from
O	606	614	baseline
O	615	617	to
O	618	619	4
O	620	625	weeks
O	626	630	post
O	630	631	-
O	631	643	radiotherapy
O	644	648	were
O	649	658	evaluated
O	659	664	every
O	665	668	two
O	669	674	weeks
O	674	675	.

O	676	679	Two
O	679	680	-
O	680	683	way
O	684	692	repeated
O	692	693	-
O	693	701	measures
O	702	707	ANOVA
O	708	716	revealed
O	717	726	different
O	727	735	patterns
O	736	738	of
B-outcome	739	746	changes
I-outcome	747	749	in
I-outcome	750	753	the
I-outcome	754	762	erythema
I-outcome	763	768	index
O	769	770	(
O	770	771	F
O	771	772	=
O	772	773	3
O	773	774	.
O	774	777	609
O	777	778	,
O	779	780	p
O	780	781	=
O	781	782	0
O	782	783	.
O	783	786	008
O	786	787	)
O	788	791	and
B-outcome	792	799	melanin
I-outcome	800	805	index
O	806	807	(
O	807	808	F
O	808	809	=
O	809	810	3
O	810	811	.
O	811	814	475
O	814	815	,
O	816	817	p
O	817	818	=
O	818	819	0
O	819	820	.
O	820	823	015
O	823	824	)
O	824	825	.

O	826	829	The
O	830	834	post
O	835	838	hoc
O	839	847	analysis
O	848	860	demonstrated
O	861	862	a
O	863	876	significantly
O	877	882	lower
B-outcome	883	891	erythema
I-outcome	892	897	index
I-outcome	898	901	and
I-outcome	902	909	melanin
I-outcome	910	915	index
O	916	918	in
O	919	922	the
O	923	931	patients
O	932	941	allocated
O	942	944	to
O	945	948	the
O	949	958	StrataXRT
O	959	964	group
O	964	965	.

O	966	969	The
O	970	973	use
O	974	976	of
O	977	986	StrataXRT
O	987	990	can
O	991	997	reduce
B-outcome	998	1007	radiation
I-outcome	1008	1018	dermatitis
O	1019	1023	with
O	1024	1031	respect
O	1032	1034	to
O	1035	1046	objectively
O	1047	1055	measured
O	1056	1069	physiological
O	1070	1074	skin
O	1075	1085	parameters
O	1085	1086	.

O	1087	1090	The
O	1091	1098	results
O	1099	1101	of
O	1102	1105	the
O	1106	1113	present
O	1114	1119	study
O	1120	1124	will
O	1125	1132	support
O	1133	1136	the
O	1137	1148	feasibility
O	1149	1151	of
O	1152	1162	conducting
O	1163	1164	a
O	1165	1171	larger
O	1172	1182	randomized
O	1183	1193	controlled
O	1194	1199	trial
O	1199	1200	.
